Trials / Conditions / Neoplasms, Nerve Tissue

Neoplasms, Nerve Tissue

16 registered clinical trials studyying Neoplasms, Nerve Tissue — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without NCT06496971	NaviFUS Corporation	Phase 3
Recruiting	Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblast NCT06329570	NaviFUS Corporation	Phase 1 / Phase 2
Terminated	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408	Blueprint Medicines Corporation	Phase 1
Terminated	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780	Blueprint Medicines Corporation	Phase 1
Recruiting	Spanish Series of Patients Treated With the Radionuclide Lutetium177 NCT04949282	Sociedad Española de Medicina Nuclear e Imagen Molecular	—
Unknown	Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. NCT04388033	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 1 / Phase 2
Unknown	External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patien NCT04697446	Blueprint Medicines Corporation	—
Terminated	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer NCT04222972	Hoffmann-La Roche	Phase 3
Completed	Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients NCT04446416	NaviFUS Corporation	N/A
Recruiting	HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388	M.D. Anderson Cancer Center	Phase 1
Completed	Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients NCT03626896	NaviFUS Corporation	N/A
Withdrawn	Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People Wi NCT03109301	National Cancer Institute (NCI)	Phase 2
Completed	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385	Hoffmann-La Roche	Phase 1 / Phase 2
Withdrawn	A Combined Cell Therapy Approach to the Treatment of Neuroblastoma NCT02745756	H. Lee Moffitt Cancer Center and Research Institute	Phase 1
Unknown	Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic NCT01579253	Ludwig-Maximilians - University of Munich	—
Approved For Marketing	Vorasidenib Expanded Access Program NCT05592743	Servier	—